Athos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Athos Therapeutics's estimated annual revenue is currently $3.1M per year.
- Athos Therapeutics's estimated revenue per employee is $77,500
- Athos Therapeutics's total funding is $60M.
Employee Data
- Athos Therapeutics has 40 Employees.
- Athos Therapeutics grew their employee count by 54% last year.
Athos Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President, CEO | Reveal Email/Phone |
2 | VP, Computational Biology | Reveal Email/Phone |
3 | VP, Analytical Chemistry | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Chairman & CMO | Reveal Email/Phone |
Athos Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Athos Therapeutics?
Developing precision therapeutics for patients with chronic inflammatory diseases incorporating artificial intelligence and machine learning algorithms
keywords:N/A
$60M
Total Funding
40
Number of Employees
$3.1M
Revenue (est)
54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Athos Therapeutics News
2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...
... Nestle, Arena Pharmaceuticals, Gilead Sciences, Galapagos, MSD, Celltrion, Sublimity Therapeutics, Sandoz, Abbott Laboratories, and Athos Therapeutics.
Other Companies in Torrance
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.6M | 40 | 29% | N/A |
#2 | $8.6M | 40 | 3% | N/A |
#3 | $7.8M | 40 | N/A | N/A |
#4 | $7.8M | 40 | -2% | N/A |
#5 | $8.6M | 40 | -5% | N/A |